THE LONG-TERM COURSE OF HEPATITIS C AFTER KIDNEY TRANSPLANTATION

1996 ◽  
Vol 62 (10) ◽  
pp. 1417-1421 ◽  
Author(s):  
Volker Kliem ◽  
Ute van den Hoff ◽  
Reinhard Brunkhorst ◽  
Hans L. Tillmann ◽  
Jakobus Flik ◽  
...  
2018 ◽  
Vol 29 (5) ◽  
pp. 1092 ◽  
Author(s):  
RadhikaChemmangattu Radhakrishnan ◽  
Basu Gopal ◽  
UdayG Zachariah ◽  
Priya Abraham ◽  
Anjali Mohapatra ◽  
...  

2010 ◽  
Vol 10 (11) ◽  
pp. 2453-2462 ◽  
Author(s):  
J. M. Morales ◽  
J. M. Campistol ◽  
B. Domínguez-Gil ◽  
A. Andrés ◽  
N. Esforzado ◽  
...  

2009 ◽  
Vol 41 (5) ◽  
pp. 1713-1716 ◽  
Author(s):  
A.C. del Pozo ◽  
J.d.R. Martín ◽  
G. Rodriguez-Laiz ◽  
M. Sturdevant ◽  
K. Iyer ◽  
...  

2001 ◽  
Vol 120 (5) ◽  
pp. A380-A380
Author(s):  
P PONSODAJR ◽  
P BLANCSR ◽  
G PHILIPPEPAGEAUXSR ◽  
J RAMOSSR ◽  
J DUCOSSR ◽  
...  

2020 ◽  
Author(s):  
Thomas Mühlbacher ◽  
Kerstin Amann ◽  
Moritz Mahling ◽  
Silvio Nadalin ◽  
Nils Heyne ◽  
...  

Abstract Recurrence of primary focal segmental glomerulosclerosis (FSGS) occurs in up to 50% of patients after kidney transplantation and is associated with poor allograft outcome. Novel therapeutic concepts directly target podocyte function via B7-1 with inconsistent response. We present the case of a 19 yr. old patient with recurrent primary FSGS early after living donor kidney transplantation. Plasmapheresis and rituximab did not induce remission. Repetitive abatacept administration was able to achieve partial remission. Maintenance immunosuppression was subsequently switched to a belatacept-based CNI-free immunosuppression, resulting in sustained complete remission with excellent allograft function throughout a follow-up of more than 56 months.


Sign in / Sign up

Export Citation Format

Share Document